Sign in
Stories
Bayer's BAY 2927088 Breakthrough Therapy Designation
Share
4D Molecular Therapeutics Raises $300 Mi...
AB Science's Medical Breakthrough Webcas...
ADC Therapeutics Reports Financial Progr...
Aldeyra Therapeutics R&D Day 2024
Aprea Therapeutics Advances WEE1 Inhibit...
Breakthrough Therapy Shows Positive Resu...
Overview
API
Bayer's BAY 2927088 receives FDA Breakthrough Therapy status for non-small cell lung cancer with HER2 mutations, showcasing potential in early trials with a collaboration involving the Broad Institute.
Ask a question
How might the Breakthrough Therapy status expedite the approval process for BAY 2927088?
In what ways could precision medicine transform the landscape of lung cancer treatment?
What implications does the collaboration with the Broad Institute hold for future cancer research?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage